Department of Urology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
Department of Urology and Urosurgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Urology. 2021 Oct;156:147-153. doi: 10.1016/j.urology.2021.04.059. Epub 2021 Jun 27.
To report feasibility and outcome of salvage robotic-assisted laparoscopic radical prostatectomy (S-RALP) after focal therapy using high-intensity focused ultrasound (HIFU) treatment compared to primary robotic-assisted laparoscopic radical prostatectomy (pRALP).
In this bicentric trial patients undergoing S-RALP for detection of WHO2016/ISUP Grade Group 2 or 3 prostate cancer were previously treated in prospective focal HIFU trials. Perioperative data, complications, oncological and functional outcome were analysed. Patients who underwent pRALP were matched in a ratio 2:1 according to preoperatively functional, oncological and clinical parameters.
A total of 39 patients were included in the study (13S-RALP, 26pRALP). Median operative time in the S-RALP group was 260minutes (pRALP: 257minutes), blood loss was 230ml (pRALP: 300ml). Complications occurred in 46.2% (6/13) of S-RALP patients (pRALP: 26.9%), including four Clavien-Dindo III complications (pRALP: 2/26). In S-RALP adverse histological outcome (≥pT3a, pN+ or R1) was detected in 23.1% (3/13) (pRALP: 26.9%). There was one patient with PSA-persistence (pRALP: 2/26). Regarding functional outcomes there was no difference between the two groups observed (incontinence P=.71, erectile function P=.21).
S-RALP should be offered to patients with an early relapse after focal HIFU. The early oncological outcome is satisfactory and functional outcome one year postoperatively is similar to pRALP. However, S-RALP is associated with a higher rate of Clavien-Dindo III complications (mainly, placement of a drainage), of which patients should be informed beforehand.
报告与原发性机器人辅助腹腔镜前列腺切除术(pRALP)相比,在高强度聚焦超声(HIFU)治疗后行挽救性机器人辅助腹腔镜前列腺切除术(S-RALP)的可行性和结果,该治疗先前用于局灶性治疗。
在这项双中心试验中,接受 S-RALP 治疗的患者先前在前瞻性局灶性 HIFU 试验中被诊断为 WHO2016/ISUP 分级组 2 或 3 前列腺癌。分析围手术期数据、并发症、肿瘤学和功能结果。根据术前功能、肿瘤学和临床参数,将接受 pRALP 的患者按 2:1 的比例匹配。
共有 39 名患者入组研究(13 名 S-RALP,26 名 pRALP)。S-RALP 组的中位手术时间为 260 分钟(pRALP:257 分钟),出血量为 230ml(pRALP:300ml)。S-RALP 组患者并发症发生率为 46.2%(6/13)(pRALP:26.9%),包括 4 例 Clavien-Dindo III 级并发症(pRALP:2/26)。在 S-RALP 中,发现 23.1%(3/13)的患者存在不良组织学结果(≥pT3a、pN+或 R1)(pRALP:26.9%)。有 1 例患者出现 PSA 持续存在(pRALP:2/26)。在功能结果方面,两组之间无差异(尿失禁 P=.71,勃起功能 P=.21)。
对于局灶性 HIFU 治疗后早期复发的患者,应考虑行 S-RALP。早期肿瘤学结果令人满意,术后 1 年的功能结果与 pRALP 相似。然而,S-RALP 与更高的 Clavien-Dindo III 级并发症发生率相关(主要是引流管放置),应提前告知患者。